NewswireToday - /newswire/ -
Ludwigshafen, Germany, 2012/11/21 - BASF plans to acquire Pronova BioPharma ASA, Lysaker, Norway, a pioneer in the field of research, development, and manufacturing of omega-3 fatty acids (Frankfurt: BAS, LSE: BFA, SWX: AN) (OBX: PRON) - BASF.com. DE000BASF111
• BASF to achieve leading position in omega-3 fatty acids;
• Cash offer of NOK 12.50 per share;
• Offer unanimously recommended by Pronova’s Board of Directors and management;
• Pre-acceptance by approximately 60% of share capital.
BASF has reached an agreement with Pronova to make a recommended voluntary public takeover offer to Pronova’s shareholders, and will offer to pay NOK 12.50 in cash for each Pronova share. The Board of Directors of Pronova and the management unanimously support BASF’s offer and recommend its acceptance.
In addition, BASF has obtained irrevocable pre-acceptance commitments for approximately 60% of Pronova’s share capital; including the 50.0% stake held by majority shareholders Herkules Private Equity Fund (held through its funds Herkules Private Equity (Jersey-I) L.P. and Herkules Private Equity (Jersey-II) L.P.), an approximately 9.1% stake indirectly controlled by investment firms Kistefos AS and Kistefos Investment AS and 0.3% held by members of the Board of Directors and management of Pronova.
The offer corresponds to a premium of 24% above the volume-weighted average share price for Pronova’s shares in the six months prior to announcement of the public takeover offer. Based on all outstanding shares and including all net financial liabilities, the enterprise value would be NOK 4,845 million (approximately €664 million). 
“The intended acquisition will significantly strengthen our position in the fast growing and highly profitable market for omega-3 fatty acids. We want to combine the global market reach and experience of BASF with the know-how of Pronova in omega-3 fatty acids,” said Michael Heinz, Member of the Board of Executive Directors of BASF SE and responsible for the Performance Products segment, which includes the Nutrition & Health division.
Highly concentrated omega-3 fatty acids are a globally growing market, d riven by an increasing consumer awareness of omega-3 fatty acids health benefits. With the acquisition of Pronova BASF will immediately achieve a leading position in the global market for omega-3 fatty acids. Pronova’s active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega-3 fatty acids, for example, in the areas of cognitive development or heart health.
The acquisition will be financed by way of available resources of BASF. The offer will be made by BASF’s wholly-owned subsidiary BASF AS in Norway and will be subject to certain conditions, including inter alia that shareholders shall in the aggregate have accepted the offer for a number of shares representing more than 90% of the total share capital of Pronova, and the same amount of votes which can be exercised in the general meeting of Pronova and that there shall have been no occurrence of a material adverse change. The offer will also be subject to approval by the relevant merger control authorities. The complete details of the offer, including all terms and conditions, will be included in an offer document complying with the requirements of the Norwegian Securities Trading Act, which is expected to be sent to Pronova’s shareholders on or about December 5, 2012. BASF expects to finalize the transaction in the first quarter of 2013.
This release is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. This release has been prepared by BASF. No representation or warranty (express or implied) of any nature is given, nor is any responsibility or liability of any kind accepted, with respect to the truthfulness, completeness or accuracy of any information, projection, statement or omission in this release. This release does not constitute, nor does it form part of, any offer or invitation to buy, sell, exchange or otherwise dispose of, or issue, or any solicitation of any offer to sell or issue, exchange or otherwise dispose of, buy or subscribe for, any securities. This release does not constitute investment, legal, tax, accountancy or other advice or a recommendation with respect to such securities, nor does it constitute the solicitation of any vote or approval in any jurisdiction. There shall not be any offer or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of any such jurisdiction (or under exemption from such requirements).
BASF (basf.com) is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success, social responsibility and environmental protection. Through science and innovation we enable our customers in almost all industries to meet the current and future needs of society. Our products and system solutions contribute to conserving resources, ensuring healthy food and nutrition and helping to improve the quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF posted sales of about €73.5 billion in 2011 and had more than 111,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN).
 Based on the current offer per share, net liabilities on September 30, 2012, and an exchange rate of €1 = NOK 7.3.
Andres-Christian Orthofer, Trade Media
P: +41 27 766-1606 - E: andres-christian.orthofer[.]basf.com.